Alvotech Reports the Initiation of Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva to Treat Bone Disease
Shots:
- The company initiates a PK study to evaluate PK, safety, and tolerability of AVT03 (denosumab) vs Prolia and Xgeva in healthy adult male patients with bone disease
- Prolia is indicated for the treatment of osteoporosis in postmenopausal and to treat bone loss in adult men and women who are at increased risk of fracture. Xgeva is indicated to prevent skeletal fractures in patients with cancer incl. bone & for giant cell tumors in bone
- The capabilities of Alvotech's biosimilars platform are demonstrated by the quick progress in the development of the product portfolio. In the EU and Canada, the company has launched AVT02 (adalimumab), a biosimilar to Humira
Ref: GlobalNewswire | Image: Alvotech
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
